5.55
-0.07(-1.25%)
Currency In CNY
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
2669
First IPO Date
April 13, 2017
| Name | Title | Pay | Year Born |
| Mr. Yi Chen | Deputy GM & Board Secretary | 0 | 1979 |
| Mr. Longxu Xie | Deputy GM & Director | 0 | 1970 |
| Mr. Zhisheng Guan | Executive Deputy GM & Non Independent Director | 0 | 1984 |
| Mr. Xiaochuan Li | Chief Medical Officer | 0 | 1965 |
| Mr. Qinghui Li | Finance Director & Accounting Supervisor | 0 | 1965 |
| Ms. Danrong Weng | Deputy General Manager | 0 | 1981 |
| Ms. Jianyu Wang | GM & Director | 0 | 1961 |
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.